How was the final diagnosis of IBD or small cell GI lymphoma determined?

• A. Endoscopic appearance alone
• B. Serum biomarkers
• C. Histopath examination after HE staining and immunophenotyping with IHC for CD21, CD79a, and CD3
• D. PCR-based profiling of biopsy DNA

Answer: (C)

Pulling together tissue architecture with cellular phenotype is essential to tell inflammatory disease from small cell GI lymphoma. A biopsy examined with hematoxylin and eosin staining shows how the tissue is organized and what the cells look like, but inflammatory bowel disease and small cell lymphoma can both produce lymphocytic infiltrates that look similar under the microscope. Immunophenotyping adds the crucial layer: staining for CD3 identifies T cells, CD79a marks B cells, and CD21 helps outline B-cell networks/follicular dendritic cell components within the lesion. This combination lets you determine the lineage of the infiltrating lymphocytes and whether the infiltrate is polyclonal and inflammatory or clonal and neoplastic. That distinction is what provides a definitive diagnosis, something that serum biomarkers or endoscopic appearance alone cannot reliably achieve. Clonality testing by PCR can support the impression, but it does not replace the information gained from histopathology combined with immunophenotyping.